Any current/future capex/capital investment/strategic investment?

n-Butylamine plant expansion progressing rapidly; expected commission in Q4 FY 2023-24 (January-March 2024). Methylamine project on track; likely commission in Q2 FY 2024-25. Dimethyl ether (DME) plant initiated in Unit IV; civil works started; expected commission first half of FY 2024-25. Proposal for new products at Unit IV: - N-Methyl Morpholine (NMM) – 3,000 TPA - N-(n-butyl) Thiophosphoric triamide (NBPT) – 2,500 TPA - Pharmapure Povidone (PVP K-30) – 4,000 TPA (all first-time products in India) Solar power plant projects for captive consumption at Unit IV (~1,600 KW, costing appro

Future growth expectations in sales/revenue/volumes?

The company expects growth and increased prospects in FY 2024-25 as market conditions improve. Ongoing projects (n-Butylamine, Methylamine, Dimethyl ether plants) are progressing on schedule, expected to add capacity. Volume improvement is anticipated post current destocking phase, with return to pre-COVID price levels within two quarters. Management is confident of margin improvement and better sales in the next two quarters. Targets to increase export contribution to 25%-30% in 1-2 years from current 15%-17% to hedge imports. Focus on new specialty products (NMM, NBPT, PVP K-30) first time i

Future growth expectations in earnings/operating earnings/profits/EPS?

The company anticipates growth and increased opportunities in FY 2024-25 as market conditions improve. Ongoing capex projects (n-Butylamine, Methylamine, Dimethyl ether) are on track and expected to enhance capacity and product portfolio. Strategic initiatives like debottlenecking and maintenance aim to improve realization, profitability, and capacity utilization. Post current quarter, the company expects a positive trend in margins and sales over the following two quarters, potentially reaching pre-COVID price levels. EPS in Q2 FY24 was INR 10.71, down from INR 16.28 in Q1 FY24 due to recent

IN US

Sale is live|00:00:00left today

Balaji Amines LtdQ3 FY23Chemicals & Petrochemicals

Balaji Amines Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,989P/E: 33.1Market Cap: ₹5.5K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→The company expects growth and increased prospects in FY 2024-25 as market conditions improve.
→Ongoing projects (n-Butylamine, Methylamine, Dimethyl ether plants) are progressing on schedule, expected to add capacity.
→Volume improvement is anticipated post current destocking phase, with return to pre-COVID price levels within two quarters.
→Management is confident of margin improvement and better sales in the next two quarters.
→Targets to increase export contribution to 25%-30% in 1-2 years from current 15%-17% to hedge imports.
→Focus on new specialty products (NMM, NBPT, PVP K-30) first time in country, and solar power initiatives for sustainability.
→Current headwinds in pharma and agrochemical segments expected to ease after this quarter.
→Expect positive volume growth noted Y-o-Y despite recent revenue pressure due to realization impact.

Margin guidance

Category 1

→The company anticipates growth and increased opportunities in FY 2024-25 as market conditions improve.
→Ongoing capex projects (n-Butylamine, Methylamine, Dimethyl ether) are on track and expected to enhance capacity and product portfolio.
→Strategic initiatives like debottlenecking and maintenance aim to improve realization, profitability, and capacity utilization.
→Post current quarter, the company expects a positive trend in margins and sales over the following two quarters, potentially reaching pre-COVID price levels.
→EPS in Q2 FY24 was INR 10.71, down from INR 16.28 in Q1 FY24 due to recent challenges.
→The company maintains a zero-debt status and targets a 25-30% export mix to hedge imports.
→Innovation with new specialty chemicals and solar power projects support long-term sustainability and growth.
→Management expects margin improvements over next 2-3 quarters as global destocking finishes and demand stabilizes.

3 more insights locked — sign up free to unlock

Fundraise plans

- The company is currently a zero-debt company on a standalone basis. - There is no explicit mention of any ongoing or planned fundraising through debt or equity in the transcript. - The company is focusing on strategic capex and new product projects for future growth. - The approach remains debt-free as emphasized by the management. - Expansion capex includes projects for n-Butylamine, Methylamine, Dimethyl Ether, and new specialty chemicals. - There is no indication of raising funds through equity either in this call. Summary: As of now, Balaji Amines Limited has not indicated any current or immediate plans for fundraising via debt or equity. The focus is on organic growth through internal accruals and strategic capex without incurring debt.

Order book

The transcript provided from the Balaji Amines Limited Q2 FY'24 Earnings Call dated November 10, 2023, does not contain specific information regarding the company's current or expected order book or pending orders. The discussion mainly focuses on: - Production updates, capacity utilization, and price trends for various products like DMF, DMC, PC, and Ethylamines. - Challenges in the specialty chemicals industry including raw material costs, destocking trends, and market competition. - Progress on ongoing capital expenditure and new plant projects. - Export markets and regulatory issues. - No direct references or disclosures about order book size, order backlog, or pending orders were mentioned. For precise figures on order book or pending orders, formal company filings or investor communications would need to be consulted.

Capex plans

Yes

→n-Butylamine plant expansion progressing rapidly; expected commission in Q4 FY 2023-24 (January-March 2024).
→Methylamine project on track; likely commission in Q2 FY 2024-25.
→Dimethyl ether (DME) plant initiated in Unit IV; civil works started; expected commission first half of FY 2024-25.
→Proposal for new products at Unit IV:
→ - N-Methyl Morpholine (NMM) – 3,000 TPA
→ - N-(n-butyl) Thiophosphoric triamide (NBPT) – 2,500 TPA
→ - Pharmapure Povidone (PVP K-30) – 4,000 TPA (all first-time products in India)
→Solar power plant projects for captive consumption at Unit IV (~1,600 KW, costing approx INR 7.5 crores) aimed at ESG compliance and reducing carbon footprint.
→Initiated maintenance and debottlenecking in existing plants to improve product mix, realization, profitability, and capacity utilization.
→Proposal to acquire additional land for future expansions, including Balaji Specialty Chemicals Unit II with environmental clearance process underway.

How does Balaji Amines Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Balaji Amines Ltd

Rev 3Mar 1

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Balaji Amines Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio